Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.64 |
| ▸ | MMP1 known ✓ | P03956 | 1/20 | 0.64 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.64 |
| ▸ | MMP13 known ✓ | P45452 | 1/20 | 0.64 |
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.49 |
| ▸ | HSP90AA1 known ✓ | P07900 | 1/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | MMP2 | P08253 | 1/20 | 0.64 |
| ▸ | MMP9 | P14780 | 1/20 | 0.64 |
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.51 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30035768 | 0.98 | CA1 (0.66) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1894783 | 0.98 | CA1 (0.66) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL5082296 | 0.96 | CA1 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL6114473 | 0.96 | CA1 (0.64) | CA1CA2MMP1MMP2MMP9 | |
| Ethylene SCHEMBL28426709 | 0.94 | CA1 (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL30957969 | 0.85 | TSHR (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL1054334 | 0.85 | TSHR (0.50) | CA1CA2MMP1MMP2MMP9 | |
| Hydrochloric Acid SCHEMBL11261755 | 0.84 | CA1 (0.62) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL29915956 | 0.83 | CA1 (0.50) | CA1CA2MMP1MMP2MMP9 | |
| SCHEMBL8863056 | 0.82 | CA1 (0.65) | CA1CA2MMP1MMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109715629-A | AZA-INDAZOLE COMPOUNDS FOR USE IN TENDON AND/OR LIGAMENT INJURIES | 诺华股份有限公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-109563103-A | modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2019-04-02 | — | — | CN | disclosed |
| CN-106103439-B | 2,7- diaza spiro [3.5] nonane compound | 瑞敏德股份有限公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-104619328-B | The condensed quinoline alkane glucocorticoid receptor modulator of heteroaryl -one | 科赛普特治疗学股份有限公司 | 2018-10-02 | — | — | CN | disclosed |
| CN-107982266-A | Carbamate compounds and its preparation and application | 阿比德治疗公司 | 2018-05-04 | — | — | CN | disclosed |
| CN-107980042-A | As ROR gamma agonists and for treating aryl dihydro -2H- benzos [b] [1,4] oxazines sulfonamide and the related compound of disease | 莱斯拉公司 | 2018-05-01 | — | — | CN | disclosed |
| CN-107531660-A | α cinnamide compounds and composition as HDAC8 inhibitor | 福马治疗股份有限公司 | 2018-01-02 | — | — | CN | disclosed |
| CN-104159581-B | Carbamate compounds and methods of making and using the same | 阿比德治疗公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-106986875-A | The conditioning agent and its application method of 5 HT acceptors | ABBVIE 公司 | 2017-07-28 | — | — | CN | disclosed |
| CN-102482292-B | Modulators of 5-HT receptors and methods of use thereof | ABBVIE 公司 | 2017-07-18 | — | — | CN | disclosed |
| US-8119633-B2 | N-{2-[2-(4-benzyl-4-hydroxy-piperidin-1-yl)-2-oxo-ethoxy]-ethyl}-N-ethyl-4-methoxy-2,3,6-trimethyl-phenylsulfonamide; condensing the N-carboxyalkyl phenylsulfonamide with the substituted piperidine; bradykinin receptor antagonists; analgesics; antidiabetics; angiogenesis inhibitors; rheumatic diseases | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119805-B2 | Substituted disulfonamide compounds | GRUENENTHAL GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| CN-102089278-A | Compounds and compositions useful for the treatment of malaria | IRM LLC | 2011-06-08 | — | — | CN | disclosed |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2010-06-17 | — | — | US | disclosed |
| US-7700654-B2 | Isolation of N-butylbenzenesulfonamide, synthesis of benzenesulfonamide derivatives, and use of N-butylbenzenesulfonamide and benzenesulfonamide derivatives for treating benign prostatic hyperplasia and/or prostate carcinoma | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2010-04-20 | — | — | US | disclosed |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2008-12-18 | — | — | US | disclosed |
| US-20080177107-A1 | Isolation of N-Butylbenzenesulfonamide, Synthesis of Benzenesulfonamide Derivatives, and Use of N-Butylbenzenesulfonamide and Benzenesulfonamide Derivatives for Treating Benign Prostatic Hyperplasia and/or Prostate Carcinoma | LTS LOHMANN THERAPIE-SYSTEME (DE) | 2008-07-24 | — | — | US | disclosed |
| CN-101065125-A | Imine compound | TAISHO PHARMACEUTICAL CO LTD (JP) | 2007-10-31 | — | — | CN | disclosed |
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | CIBA SPEICIALTY CHEMICALS CORP. | 2001-11-01 | — | — | US | disclosed |
| US-6017675-A | POLYMERIZATION CATALYST | CIBA SPECIALTY CHEMIALS CORPORATION (US) | 2000-01-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080177107-A1 | Isolation of N-Butylbenzenesulfonamide, Synthesis of Benzenesulfonamide Derivatives, and Use of N-Butylbenzenesulfonamide and Benzenesulfonamide Derivatives for Treating Benign Prostatic Hyperplasia and/or Prostate Carcinoma | BPHL, BRDT, NBAS | CA2 977/4885MMP1 892/4885MMP8 733/4885 |
| US-20100152158-A1 | Substituted Disulfonamide Compounds | BDKRB1, BDKRB2, BRS3 | CA2 1752/4885MMP1 3232/4885MMP8 3091/4885 |
| US-20080312231-A1 | Substituted Sulfonamide Compounds | SULT2A1, SULT1A1, SCN1A | CA2 673/4885MMP1 3578/4885MMP8 1567/4885 |
| US-20010037037-A1 | Oximesulfonic acid esters and the use thereof as latent sulfonic acids | QSOX1, HAO2, PAH | CA2 220/4885MMP1 1926/4885MMP8 3748/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.